Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX: Capecitabine, Bevacizumab, and Mitomycin C in Metastatic Colorectal Cancer
NCT00294359Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2005
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of bevacizumab, mitomycin c in metastatic colorectal cancer (mCRC), sponsored by Australasian Gastro-Intestinal Trials Group. Started Jun 2005; status: completed.
02
Drugs
bevacizumabmitomycin c
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00294359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294359.